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RESEARCH
MMP9 modulation improves specific 
neurobehavioral deficits in a mouse model 
of Alzheimer’s disease
Charis Ringland1,2, Jonas Elias Schweig1, Maxwell Eisenbaum1,2, Daniel Paris1, Ghania Ait‑Ghezala1,2, 
Michael Mullan1,2, Fiona Crawford1,2,3, Laila Abdullah1,2,3 and Corbin Bachmeier1,2,4* 
Abstract 
Background: Matrix metallopeptidase 9 (MMP9) has been implicated in a variety of neurological disorders, including 
Alzheimer’s disease (AD), where MMP9 levels are elevated in the brain and cerebrovasculature. Previously our group 
demonstrated apolipoprotein E4 (apoE4) was less efficient in regulating MMP9 activity in the brain than other apoE 
isoforms, and that MMP9 inhibition facilitated beta‑amyloid (Aβ) elimination across the blood–brain barrier (BBB)
Methods: In the current studies, we evaluated the impact of MMP9 modulation on Aβ disposition and neurobehav‑
ior in AD using two approaches, (1) pharmacological inhibition of MMP9 with SB‑3CT in apoE4 x AD (E4FAD) mice, 
and (2) gene deletion of MMP9 in AD mice (MMP9KO/5xFAD)
Results: Treatment with the MMP9 inhibitor SB‑3CT in E4FAD mice led to reduced anxiety compared to placebo 
using the elevated plus maze. Deletion of the MMP9 gene in 5xFAD mice also reduced anxiety using the open 
field test, in addition to improving sociability and social recognition memory, particularly in male mice, as assessed 
through the three‑chamber task, indicating certain behavioral alterations in AD may be mediated by MMP9. How‑
ever, neither pharmacological inhibition of MMP9 or gene deletion of MMP9 affected spatial learning or memory in 
the AD animals, as determined through the radial arm water maze. Moreover, the effect of MMP9 modulation on AD 
neurobehavior was not due to changes in Aβ disposition, as both brain and plasma Aβ levels were unchanged in the 
SB‑3CT‑treated E4FAD animals and MMP9KO/AD mice compared to their respective controls.
Conclusions: In total, while MMP9 inhibition did improve specific neurobehavioral deficits associated with AD, such 
as anxiety and social recognition memory, modulation of MMP9 did not alter spatial learning and memory or Aβ tis‑
sue levels in AD animals. While targeting MMP9 may represent a therapeutic strategy to mitigate aspects of neurobe‑
havioral decline in AD, further work is necessary to understand the nature of the relationship between MMP9 activity 
and neurological dysfunction.
Keywords: Alzheimer’s disease, Matrix metallopeptidase 9, Apolipoprotein E, Social recognition memory, Beta‑
amyloid
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Background
Matrix metalloprotease 9 (MMP9) is a type IV colla-
genase and a member of the endopeptidase family of pro-
teins, which contribute to tissue remodeling by degrading 
extracellular matrix components. MMP9 is expressed 
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from the cell as a pro-MMP9 precursor, before being 
activated extracellularly [123]. MMP9 has been impli-
cated in a variety of neurological and inflammatory dis-
ease states and elevated MMP9 levels have been reported 
in cerebrovascular disorders such as Alzheimer’s disease 
(AD) [1–3], cerebral amyloid angiopathy [4], ischemia [5, 
6], and intracerebral hemorrhage [7]. With respect to AD, 
studies have shown that MMP9 brain levels were elevated 
in patients with moderate and late AD [8] and MMP9 
levels in cerebrospinal fluid (CSF) were associated with 
faster decline in an MCI to AD conversion group [9]. In 
other words, in these studies, higher levels of MMP9 in 
the brain and CSF were associated with later-stage AD 
[8] and correlated with declines in hippocampal volume 
and cognitive function [9]. Moreover, MMP9 has been 
found to play a causal role in amyloid β (Aβ)-induced 
cognitive impairment and neurotoxicity [10], as intrac-
erebroventricular injection of Aβ induced cognitive defi-
cits and MMP9 expression in the mouse hippocampus, 
while Aβ exposure caused neurotoxicity in cultured neu-
rons. Importantly, the Aβ-induced cognitive impairment 
in vivo as well as neurotoxicity in vitro was significantly 
alleviated in MMP-9 homozygous knockout (KO) mice 
and treatment with MMP inhibitors [10].
Apolipoprotein E (APOE) is a major genetic risk fac-
tor for AD and has been shown by our group and oth-
ers to influence Aβ clearance from the brain in an 
isoform-specific manner, with apoE4 being associated 
with reduced blood–brain barrier (BBB) transit from 
the brain [11–15]. Our team also found an isoform-spe-
cific effect of apoE on the ectodomain shedding of low-
density lipoprotein receptor (LDLR) and LDLR-related 
protein 1 (LRP1) in brain endothelia with a rank order 
of apoE4 > apoE3 > apoE2 [16]. Importantly, these find-
ings showed an inverse relationship between lipoprotein 
receptor shedding in the brain and Aβ elimination across 
the BBB, one that is APOE-genotype specific [16]. Our 
prior studies suggest the effect of apoE on these pro-
cesses may be mediated through MMP9 [17, 18]. Based 
on in vitro and ex vivo studies, MMP9 is able to bind and 
proteolyse lipoprotein receptors prompting ectodomain 
shedding [19–22]. The proteolytic shedding of LRP1 and 
LDLR by MMP9 impairs their ability to transport Aβ out 
of the brain [16, 17]. Previously, we have shown that apoE 
influences MMP9 disposition in the brain in an isoform-
dependent manner [18]. We demonstrated that apoE 
influences MMP9 levels in brain endothelia, the conver-
sion of proMMP9 to active MMP9, and dose-depend-
ently inhibits MMP9 activity. Importantly, apoE4 was the 
least effective in modulating these processes compared 
to other apoE isoforms, which may be due to a weaker 
binding affinity to MMP9 [18]. Furthermore, with respect 
to AD, MMP9 levels were significantly elevated in the 
cerebrovasculature of both human and animal AD brain 
specimens with an APOE4 genotype [18].
It has been demonstrated that MMP9 knockout 
(MMP9KO) mice were protected against cerebral 
ischemia [23] and traumatic brain injury [24], reportedly 
due to the prevention of MMP9 activity at the BBB. Phar-
macologic inhibition of MMPs has been shown to attenu-
ate tissue damage and edema in cerebral focal ischemia 
[25, 26] and ameliorate neutrophil infiltration, oxidative 
stress, edema and degenerating neurons in intracerebral 
hemorrhage [7]. In a transgenic mouse model of AD, 
minocycline treatment diminished inducible nitric oxide 
synthase and activation of microglia whilst ameliorating 
cognitive dysfunction which was attributed in part to the 
inhibition of MMP9 [27]. Lastly, intracranial injection of 
Aβ increased MMP9 expression and induced hippocam-
pal damage alongside learning and memory deficits [10, 
28–30], which was alleviated by MMP9 inhibitors and 
diminished in MMP9KO mice [10].
Despite its implications in AD and other neurologi-
cal disorders, MMP9 has not been formally investigated 
as a target in AD models. The elevated MMP9 levels in 
AD brains and the reduced ability of apoE4 to modulate 
MMP9 disposition in our prior studies [18] prompted us 
to investigate the therapeutic value of modulating MMP9 
activity in E4FAD transgenic animals, an AD mouse 
model expressing five familial AD (FAD) mutations 
(5xFAD mice) and homozygous for the human APOE4 
gene. To assess the impact of modulating MMP9 activity 
on the AD phenotype, we used SB-3CT which has been 
recognized as a selective MMP-2 and MMP9 inhibitor [6, 
31–33]. This compound readily crosses the BBB and was 
developed to circumvent the adverse side-effects associ-
ated with broad-spectrum MMP inhibitors [34, 35]. In 
addition to pharmacological inhibition of MMP9 in AD 
animals, we generated 5xFAD/MMP9 knockout mice 
(MMP9KO mice crossed with 5xFAD mice) as a com-
plementary approach to evaluating the effect of MMP9 
modulation on AD pathology and neurobehavior. Specifi-
cally, in the following studies we assessed the influence 
of pharmacological MMP9 inhibition and MMP9 gene 
knockout on amyloid pathology and lipoprotein recep-
tor shedding in the brain alongside several measures of 
behaviour including anxiety, sociability, social recogni-
tion memory, and spatial learning and memory.
Methods
Materials
The MMP9 inhibitor, SB-3CT (2-[[(4-Phenoxyphenyl)
sulfonyl]methyl]thiirane), was purchased from Tocris 
Bioscience (Minneapolis, MN, USA). Enzyme linked 
immunosorbent assay (ELISA) kits for mouse MMP9 
were purchased from Sciencell Research Laboratories 
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(Carlsbad, CA, USA). ELISA kits for LDLR and LRP1 
receptors were purchased from Cedarlane Labs (Burl-
ington, NC, USA). Halt enzyme inhibitor cocktails, the 
bicinchoninic acid (BCA) protein assay, Hanks Balanced 
Salt Solution (HBSS) and ELISA kits for human Aβ-40 
and Aβ-42 were purchased from Thermo Fisher Scientific 
(Waltham, MA, USA). Dextran was purchased from Mil-
liporeSigma (St. Louis, MO, USA).
Animals
5xFAD mice
The 5xFAD mice are APP/PS1 double transgenic mice 
that co-express five FAD mutations and were purchased 
from the Jackson Laboratory (Bar Harbor, ME, USA). 
These mice are hemizygous for the amyloid precursor 
protein (APP) and presenilin 1 (PSEN1) transgenes on a 
congenic C57BL/6 background and display elevated lev-
els of cerebral Aβ and accelerated Aβ plaque develop-
ment in the brain, representing some of the pathological 
features of AD [36].
EFAD mice
ApoE-TR mice were purchased from Taconic Biosciences 
(Rensselaer, NY). The apoE-TR mice were created by 
targeted replacement of the endogenous murine APOE 
gene with human APOE2, APOE3 or APOE4 [37] {Sul-
livan, 1997 #285}. These mice retain the endogenous 
regulatory sequences required for apoE production and 
express the human apoE protein at physiological levels. 
The EFAD animals were provided by Dr. Mary Jo LaDu 
(University of Illinois at Chicago). To generate the EFAD 
mouse model, 5xFAD mice (Tg6799 line) were crossed 
with apoE4, apoE3, and apoE2-TR mice, producing the 
E4FAD, E3FAD, and E2FAD mouse models respectively, 
as previously described [38].
MMP9KO mice
MMP9KO mice and their C57BL/6 controls were pur-
chased from the Jackson Laboratory (Bar Harbor, ME, 
USA) and allowed to adapt to the vivarium for 2 weeks 
prior to any breeding or experimental procedures. 
MMP9KO mice were generated as previously described 
and are viable, fertile and shown to survive for at least 
24 months [39].
Generation of the 5xFAD/MMP9KO mice
The genetic manipulation of MMP9 levels was inves-
tigated by crossing MMP9KO mice with 5xFAD mice 
(both strains were on a C57BL/6 background). 5xFAD 
mice, hemizygous for the APP and PSEN1 transgenes 
were initially crossed with MMP9KO mice which were 
null for the MMP9 gene. The resulting litters were all 
heterozygous for the MMP9 gene, half were positive 
for the 5xFAD mutations (5xFAD/MMP9KO-het) and 
half were negative (wild type (WT)/MMP9KO-het). 
The 5xFAD/MMP9KO-het mice were then backcrossed 
with the MMP9KO mice to generate 5xFAD/MMP9KO, 
WT/MMP9KO (MMP9KO), 5xFAD/MMP9KO-het 
and WT/MMP9KO-het mice. Concurrent breeding of 
5xFAD and WT mice generated the cohort of 5xFAD and 
WT control mice used for the study. Gender matched, 
6-month-old WT, 5xFAD, 5xFAD/MMP9KO, 5xFAD/
MMP9KO-het and MMP9KO mice were used in this 
study (n = 12, 6 males, 6 females). 5xFAD/MMP9KO-het 
mice were only used for pathological analyses.
Housing
Mice were housed under standard laboratory conditions 
(23 ± 1 °C, 50 ± 5% humidity, and a 12-h light/dark cycle) 
with free access to food and water throughout the study. 
Mice were multi-housed through the elevated plus maze 
(EPM), open field test (OFT) and three-chamber tests. 
All experiments using animals were performed under 
protocols approved by the Institutional Animal Care and 
Use Committee of the Roskamp Institute.
SB‑3CT treatment paradigm and timeline for behavioral 
analyses
For the pharmacological treatment studies, 4-month-old 
E4FAD mice were injected intraperitoneally with either 
SB-3CT (25 mg/kg) dissolved in 25% dimethyl sulfoxide 
(DMSO)/65% Polyethylene glycol (PEG)-40/10% water 
or vehicle (25% DMSO/65% PEG-40/10% water alone). 
It was previously reported that seven days of treatment 
with this concentration of SB-3CT effectively inhibited 
MMP9 in a mouse model of focal cerebral ischemia [31]. 
SB-3CT was designed as a highly selective inhibitor to 
MMP-2 and MMP-9 with a Ki value of 2.1 nM for MMP-
9. Moreover, SB-3CT has a reported brain to plasma 
AUC ratio of 0.68 and readily distributes throughout the 
brain, indicating SB-3CT adequately permeates the BBB 
[35]. The reported elimination half-life of SB-3CT in mice 
after repeated doses was 53  min [32], using the same 
dose (25  mg/kg) and route of administration (intraperi-
toneal) as the current studies. In total, 28 animals were 
treated, divided into two groups balanced for gender and 
weight (E4FAD-vehicle, n = 14 (5 × males, 9 × females), 
E4FAD-SB-3CT, n = 14 (5 × males, 9 × females)). Male 
and female mice weighed on average 32.41 ± 0.97  g and 
21.57 ± 0.21 g, respectively.
Study design
Daily intraperitoneal injections (approximately 5PM 
each day) of vehicle or SB-3CT (25 mg/kg) were admin-
istered to 4-month-old E4FAD mice for a period of 
4 weeks (Fig. 1a), for a total of 22 injections. Behavioural 
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analysis began 2 weeks after the first injection and mice 
were euthanized 24  h after the last injection of the 
4 week treatment paradigm. For the genetic MMP9 dele-
tion studies, behavioural analyses were performed in 
WT, 5xFAD, 5xFAD/MMP9KO and MMP9KO mice at 
22  weeks of age and mice were euthanized at 26  weeks 
of age (Fig.  1b), alongside the 5xFAD/MMP9KO-het 
mice which were used only for the pathological analyses. 
Euthanasia was performed using 5% isoflurane in oxygen 
via inhalation using a vaporizer at 1 L/min, followed by 
decapitation.
Behavioral analysis
Evaluation of anxiety‑related behavior and motor activity 
in mice
Motor function and anxiety were assessed in E4FAD 
mice after 2  weeks of treatment with either SB-3CT 
(25  mg/kg) or vehicle using the elevated plus maze and 
the open field test. These same tests were utilized in the 
MMP9 gene deletion studies to evaluate the WT, 5xFAD, 
5xFAD/MMP9KO and MMP9KO animals. The EPM 
consists of an elevated area (0.5 m) with two open arms 
and two closed arms with 15 cm high walls and an open 
roof (similar arms are opposite each other) [40]. Mice 
were individually placed in the center of the maze and 
movements were tracked using the EthoVision software 
for 5  min (Noldus, VA, USA). Mice were scored based 
on the number of entries into closed vs open arms and 
the time spent in closed vs open arms. An increase in 
open arm activity indicates anti-anxiety behavior [41]. 
The OFT is a common measure of exploratory behavior 
and general activity in mice [42–44]. The mice were indi-
vidually placed into an enclosure with surrounding walls 
and an open roof and movements were tracked using 
the EthoVision software for 10  min (Noldus, VA, USA). 
Mice were scored based on the number of entries into the 
center, middle and outer edges of the arena and the time 
spent in these three areas. An increase in duration/num-
ber of entries into the center area indicates anti-anxiety 
behavior [42–44]. The distanced travelled by the animal 
in the OFT provides a measure of motor activity [42, 43].
Assessment of social interaction and social memory in mice
The three-chamber test was used to measure cognition 
in the form of general sociability and interest in social 
novelty [45] in the E4FAD mice following 2.5  weeks of 
SB-3CT treatment. Additionally this test was used in the 
MMP9 gene deletion studies to evaluate the WT, 5xFAD, 
5xFAD/MMP9KO and MMP9KO animals. In this test, 
mice were placed individually into the center chamber of 
a box arena with three equally sized chambers and open-
ings between the chambers. A schematic of the setup is 
displayed in Figs. 3 and 10. The two side chambers con-
tained a wire cup through which the subject mouse can 
have indirect interaction with the novel and familiar 
mice. This test consisted of three 10-min experimental 
sessions with different setups. In all sessions, the subject 
mouse could explore the whole arena. In the first session 
(habituation) the two side chambers remained empty to 
give the mice time to explore and become familiar with 
Fig. 1 Study design for the 4‑week pharmacological MMP9 inhibition and MMP9 gene deletion in vivo analysis. A Study 1. MMP9 was 
pharmacologically inhibited in E4FAD mice through a 4‑week treatment with vehicle or SB‑3CT (25 mg/kg), injected intraperitoneally (IP). B Study 
2. MMP9KO mice were crossed with 5xFAD mice to create 5xFAD/MMP9KO mice, which were tested alongside WT, 5xFAD and MMP9KO mice. 
Behavioral analysis consisted of the elevated plus maze (EPM), open field test (OFT), three chamber test and the radial arm water maze (RAWM). 
MMP Matrix metallopeptidase, E4FAD Apolipoprotein E4 x Familial Alzheimer’s disease, MMP9KO MMP9 knockout, WT Wild‑type
Page 5 of 25Ringland et al. BMC Neurosci           (2021) 22:39  
the arena. In the second session (test for social interac-
tion), a mouse was added to the wire cup in one side 
chamber. In the third session (test for social memory), 
a novel mouse was placed in the wire cup in the oppo-
site side chamber to the now familiar mouse. Positions 
of the novel and familiar mice were changed between tri-
als to avoid side bias. Time spent in each chamber, time 
spent in the immediate area surrounding the wire cup, 
and the number of entries into each area were recorded. 
The test for social interaction measured the time spent 
with another mouse compared to time spent alone in an 
identical but empty chamber. The test for social memory 
measured the preference for a novel vs familiar mouse 
[45].
Assessment of spatial memory in mice
Spatial memory and learning was assessed in E4FAD 
mice after 3  weeks of treatment with either vehicle or 
SB-3CT using the radial arm water maze (RAWM) [46]. 
This test was also used in the MMP9 gene deletion stud-
ies evaluating the WT, 5xFAD, 5xFAD/MMP9KO and 
MMP9KO animals. The RAWM consists of a circular 
water-filled maze with six arms extending from an open 
central area that are distinguishable by unique visual 
cues on the end of each arm. A schematic of the setup 
is displayed in Figs. 4 and 12. The mice were placed into 
one of the five entry arms (alternated between trials) and 
the task was to find the hidden platform in the sixth arm 
(goal arm), which remained constant. Each trial ended 
after one minute and errors were calculated after track-
ing the movements using the EthoVision software (Nol-
dus, VA, USA). Entry into an incorrect arm was scored as 
an error. The total number of incorrect errors made per 
trial before finding the hidden platform reflects reference 
memory, while the number of incorrect re-entries (multi-
ple entries into the same arm) indicates working memory. 
The mice underwent nine trials per day for a total of five 
consecutive days. By the last day of trials, mice that have 
correctly learned the location of the hidden platform 
demonstrate errors of 1 or less and show improvement 
between trials [46]. Latency to reach the hidden platform 
was also recorded and analyzed.
Isolation of brain fractions
Mouse brains were homogenized and the cerebrovascula-
ture, parenchyma and soluble brain fraction were isolated 
using a step-wise density gradient extraction process as 
previously described [16]. Briefly, mouse brain samples 
were homogenized in cold HBSS using a Dounce homog-
enizer. The homogenates were suspended in HBSS with 
20% dextran and centrifuged for 15  min at 6000  g and 
4 °C. The cerebrovascular pellet at the bottom of the tube 
was gently rinsed in HBSS and collected with lysis buffer 
(mammalian protein extraction (M-PER) reagent + 1% 
ethylenediaminetetraacetic acid (EDTA) + 0.2% phenyl-
methylsulphonyl fluoride (PMSF) (Thermo Scientific, 
USA)) supplemented with Halt protease and phosphatase 
inhibitor cocktail (Thermo Scientific, USA). The remain-
ing parenchyma and soluble brain fraction (i.e., non-
cell associated) were centrifuged for a further 10 min to 
separate these two fractions. The parenchyma was resus-
pended in HBSS and centrifuged for a final 5 min before 
the pellet was collected in lysis buffer. All fractions were 
stored at −  80  °C prior to analysis. Quantification of 
Aβ40 and Aβ42 in the whole parenchyma, cerebrovascu-
lar and plasma fractions was carried out using an ELISA 
for human Aβ40 and Aβ42 (Invitrogen, USA).
Zymographic analysis of EFAD spleen samples
Spleen samples from SB-3CT and placebo-treated E4FAD 
mice were analyzed for MMP9 content through zymo-
graphic analysis. Lysis buffer (M-PER + 1% EDTA + 0.2% 
PMSF (Thermo Scientific, USA)) supplemented with Halt 
protease and phosphatase inhibitor cocktail (Thermo 
Scientific, USA) was added to spleen samples collected 
from EFAD mice before they were homogenized via 
sonication (Sonic Dismembrator model 100, T). Samples 
were centrifuged to remove cell debris before analysis by 
gelatin zymography to determine pro and active MMP9 
levels. Equal protein quantities of each sample (50  µg) 
were incubated with Gelatin-Sepharose® 4B (GE Health-
care, Chicago IL) to concentrate the MMP9. Samples 
were incubated with the beads for 1–2  h at room tem-
perature with rotation, and then centrifuged at 6000 rpm 
for 2 min. Gelatinases were eluted in equal amounts (25 
µL) of 1X Zymogram sample buffer (Bio-Rad, Hercules, 
CA, USA) before being separated on a 10% precast poly-
acrylamide gel with gelatin (Thermo Fisher Scientific, 
Waltham, MA, USA). The gel was incubated in Triton 
X-100 (Zymogram Renaturation Buffer, Thermo Fisher 
Scientific, Waltham, MA, USA) for 30 min at room tem-
perature with gentle agitation to renature the proteins. 
The gel was next incubated in development buffer con-
taining 50 mM Tris–HCl, pH 7.5, 200 mM NaCl, 5 mM 
CaCl2, 0.02% Brij-35 (Zymogram Development Buffer, 
Thermo Fisher Scientific, Waltham, MA, USA) for 18 h at 
37 °C to initiate enzyme activity. The gel was stained with 
0.5% Coomassie blue (Bio-Rad, Hercules, CA, USA) for 
one hour and washed in destaining solution (45% deion-
ised water, 45% methanol, 10% acetic acid) before being 
scanned with the Universal Hood II (Bio-Rad, Hercules, 
CA, USA).
Statistical analysis
Data are expressed as mean ± standard error of the mean 
(SEM). Data was checked for normality and statistical 
Page 6 of 25Ringland et al. BMC Neurosci           (2021) 22:39 
significance was determined by analysis of variance 
(ANOVA) followed by the two-stage step-up method of 
Benjamini, Krieger and Yekutieli (BKY) unless otherwise 
stated. A p-value lower than 0.05 was used to indicate 
a statistically significant difference. Statistical analyses 
were performed with GraphPad Prism 8.
Results
Pharmacological inhibition of MMP9 activity with SB‑3CT 
in E4FAD mice
SB‑3CT treatment influenced anxiety levels but not motor 
activity in E4FAD mice
Following 2  weeks of daily SB-3CT injections, the EPM 
and the OFT revealed no differences in total distance 
travelled or average velocity between the SB-3CT-treated 
and vehicle-treated mice (Fig. 2b, c, e, f ), indicating the 
drug treatment does not alter locomotor activity. Fur-
thermore, while no effects in anxiety were demonstrated 
in the OFT (Fig. 2a), SB-3CT-treated mice spent signifi-
cantly more time in the closed arm compared to con-
trol animals in the EPM (*p < 0.05) (Fig. 2d). There were 
no gender differences observed in either the EPM or the 
OFT.
SB‑3CT treatment did not impact social interaction, social 
memory, or spatial memory
E4FAD mice treated with either SB-3CT or vehicle 
showed no preference for the chamber or proximal 
zone containing a mouse compared to an empty cage in 
the three-chamber test (Fig.  3a, b). Furthermore, there 
were no differences between either group in the time 
spent with a novel mouse compared to a familiar mouse 
(Fig.  3c, d). Moreover, there were no gender differences 
observed in the three-chamber test. In the RAWM, no 
differences between the SB-3CT or vehicle-treated mice 
were observed in the number of incorrect entries made 
before finding the hidden platform (Fig. 4b), the latency 
to find the platform (Fig. 4c), the average distance trav-
elled per trial (Fig.  4d) or the average velocity (Fig.  4e). 
Overall mice in both treatment groups continued to learn 
and improve each of the 5  days, making few incorrect 
entries and finding the hidden platform relatively quickly. 
When stratified for gender (Fig. 5a, b, c, d, e), male mice 
treated with SB-3CT displayed a slightly reduced latency 
to find the hidden platform, however this was not statisti-
cally significant (Fig. 5c).
Brain Amyloid levels were similar in SB‑3CT 
and vehicle‑treated E4FAD mice
Aβ-40 and Aβ-42 levels were evaluated in the brain 
parenchyma fractions of SB-3CT and vehicle-treated 
E4FAD mice. The whole parenchyma brain frac-
tion was analyzed in addition to Aβ-42 levels in the 
cerebrovasculature of each mouse. While no differences 
in Aβ-40 and Aβ-42 levels were observed in any brain 
fraction when comparing SB-3CT to vehicle-treated ani-
mals, Aβ-40 and Aβ-42 levels were higher in female mice 
compared to male mice in the whole parenchyma brain 
fraction (*p < 0.05, **p < 0.01, ***p < 0.001) (Fig. 6).
LDLR and LRP1 levels were unchanged across treatment 
groups in E4FAD mice
LDLR and LRP1 were measured in the cerebrovascula-
ture and soluble brain fraction of SB-3CT and vehicle-
treated E4FAD mice (Fig. 7). The levels of both receptors 
were not different between the SB-3CT and vehicle-
treated groups for both brain fractions of (Fig. 7a, b, c, d). 
Moreover, there were no gender differences observed in 
the analysis of LDLR or LRP1.
Pro and total MMP9 levels were unaltered by SB‑3CT 
treatment
To examine the effects of the MMP9 inhibitor (SB-3CT) 
on MMP9 activity, the spleens of each mouse were 
examined via zymography (Fig. 8a, b), owing to the high 
expression levels of MMP9 in this tissue type [47–49]. 
ProMMP9 levels were detected in the spleens of the 
mice; however, no differences were identified between 
mice treated with SB-3CT or vehicle (Fig. 8a, b). Of note, 
neither pro-MMP9 nor active MMP9 levels were high 
enough in the mouse brain tissue samples to be detected 
via zymographic analysis and therefore these analyses 
were restricted to spleen samples only. To investigate 
whether total MMP9 expression levels in the brain were 
altered by SB-3CT treatment, cerebrovasculature and 
parenchyma brain samples were analyzed for MMP9 
using an ELISA. No differences in total MMP9 levels 
were identified between SB-3CT and vehicle-treated 
mice in either fraction (Fig. 8c, d). Of note, no side effects 
or signs of toxicity were observed with this treatment 
paradigm, consistent with previous reports administering 
SB-3CT to mice using the same dose and a similar treat-
ment regimen as the current studies [31, 32].
Genetic manipulation of MMP9 in 5xFAD mice
Anxiety and motor function differ between 5 and 5xFAD/
MMP9KO mice
The OFT demonstrated that 5xFAD mice exhibit 
reduced anxiety compared to all other genotypes 
(Fig.  9a). The WT, 5xFAD/MMP9KO, and MMP9KO 
mice spent more time in proximity to the outer walls 
of the arena, while 5xFAD mice spent significantly 
less time in this area (**p < 0.01). Instead, 5xFAD mice 
spent significantly more time in the middle area of the 
arena, away from the walls, than the other genotypes 
(*p < 0.05) (Fig.  9a). For the EPM, results showing the 
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time spent in the closed and open arms indicate the 
5xFAD mice spent less time in the closed arms com-
pared to MMP9KO mice (*p < 0.05), but no signifi-
cant difference was observed between the 5xFAD and 
WT mice (Fig.  9d). In the OFT, the total distance 
travelled and the average velocity were both reduced 
in 5xFAD/MMP9KO compared to 5xFAD and WT 
mice (*p < 0.05, **p < 0.01) (Fig.  9b, c). In the EPM, 
these parameters were both increased in 5xFAD mice 
compared to 5xFAD/MMP9KO and MMP9KO mice 
(*p < 0.05) (Fig.  9e, f ). There were no gender differ-
ences observed in either the EPM or the OFT.
Fig. 2 Anxiety‑related behavior and locomotor activity in the OFT and the EPM. SB‑3CT and vehicle‑treated E4FAD mice were tested using A, B, C 
the OFT and D, E, F, the EPM. A For the OFT, the duration spent in the outer, middle and center areas of the circular arena was measured along with 
B the total distance travelled and C the average velocity. D For the EPM, the duration spent in the closed and open arms was measured together 
with E the total distance travelled and F the average velocity. Animals were approximately 5 months of age and values represent mean ± SEM 
(N = 14, 5 males, 9 females for each group). Statistical significance was determined by A, D ANOVA followed by the BKY procedure and B, C, E, F an 
unpaired t‑test. *p < 0.05. EPM Elevated plus maze, OFT Open field test, E4FAD Apolipoprotein E4 x Familial Alzheimer’s disease, SEM Standard error of 
the mean, ANOVA Analysis of variance, BKY Benjamini, Krieger, and Yekutieli
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Genetic deletion of MMP9 rescues social memory deficits 
in 5xFAD mice
The EPM and OFT were followed by the three-cham-
ber test to assess social interaction behavior (general 
sociability) and interest in social novelty. Regarding 
sociability, all genotypes spent significantly more time 
in the chamber with another mouse compared to the 
chamber with an empty cage (*p < 0.05, **p < 0.01, 
***p < 0.001) (Fig. 10a). When examining the time spent 
in close proximity to the empty cage or the cage con-
taining a mouse, again, all genotypes spent more time 
in the proximal zone surrounding the cage contain-
ing the mouse compared to the empty cage (*p < 0.05, 
**p < 0.01, ***p < 0.001, ****p < 0.0001) (Fig.  10b). How-
ever, 5xFAD mice spent significantly less time inter-
acting with the mouse compared to the WT group 
(p < 0.05) (Fig.  10b). Following the introduction of a 
novel mouse in the test for social memory, WT, 5xFAD/
MMP9KO and MMP9KO mice all spent significantly 
more time with the novel mouse compared to the famil-
iar mouse. Conversely, the 5xFAD mice did not show a 
significant preference for either the novel or the famil-
iar mouse (Fig.  10c, d). Overall, 5xFAD mice showed 
a lack of social interaction and increased deficits in 
social memory as demonstrated by a greater disinterest 
in exploring the novel mouse compared to the empty 
cage, and the novel mouse compared to the familiar 
mouse, respectively. Notably, this was not observed in 
the 5xFAD/MMP9KO mice, which exhibited behavior 
akin to the WT and MMP9KO mice (Fig. 10c, d). Fur-
ther analysis of this data revealed that these observed 
differences were driven by the male mice in each group 
(Fig.  11). When analyzing the males alone, the previ-
ously observed differences were more pronounced and 
additional differences were identified. For example, 
when examining the proximal zone near the cages con-
taining the mice, male 5xFAD/MMP9KO mice spent 
significantly more time with the novel mouse compared 
to the familiar mouse (*p < 0.05) (Fig. 11d).
No deficits in spatial memory were identified in 5xFAD 
or 5xFAD/MMP9KO mice
Following evaluation in the three-chamber test, The 
RAWM was used to investigate working and reference 
memory (Fig. 12a). Analysis of the WT, 5xFAD, 5xFAD/
MMP9KO or MMP9KO mice in the RAWM revealed no 
differences in the number of incorrect entries made for 
any genotype (Fig.  12b). All genotypes made gradually 
fewer mistakes as the trials progressed and the time taken 
to reach the platform also decreased by day 5 of testing, 
and no differences between genotypes were identified 
(Fig.  12c). The number of incorrect re-entries (multiple 
entries into the same arm per trial) was also assessed, but 
after day 1 this type of error was no longer committed. 
When examining the distance travelled and the aver-
age velocity, no differences were detected between any 
of the groups (Fig.  12d, e). Additionally, there were no 
gender differences observed in the RAWM for any of the 
genotypes.
Amyloid levels were similar across genotypes
Aβ-40 and Aβ-42 levels were evaluated in the cerebrovas-
culature and the brain parenchyma fractions of 5xFAD, 
5xFAD/MMP9KO and 5xFAD/MMP9KO-het mice 
(Fig.  13, 14). WT and MMP9KO mice were excluded 
from analysis due to negligible Aβ levels. In addition, 
Aβ-40 levels were analyzed in the plasma of each mouse 
(Fig. 13). While no differences in Aβ-40 and Aβ-42 lev-
els were observed in any brain fraction when comparing 
each genotype, amyloid levels were higher in female mice 
compared to male mice (*p < 0.05, **p < 0.01, ***p < 0.001) 
(Fig. 13, 14).
LDLR and LRP1 levels
LDLR and LRP1 levels were examined in WT, 5xFAD, 
5xFAD/MMP9KO, 5xFAD/MMP9KO-het and MMP9KO 
mice to determine the effect of MMP9 gene deletion on 
lipoprotein receptor shedding (Fig. 15). No differences in 
these receptors were detected between any genotype in 
the soluble brain fraction (Fig. 15a, c) or isolated cerebro-
vasculature (Fig.  15b, d). There were no gender differ-
ences observed in the analysis of LDLR or LRP1 for any 
of the genotypes.
Discussion
Elevated MMP9 levels are apparent in a variety of neu-
rological disorders where they have been shown to per-
petuate disease progression [4–7, 50–54]. As our prior 
studies showed MMP9 levels and activity are elevated 
in the presence of the apoE4 isoform in AD [18], and 
Fig. 3 Testing social interaction and social memory using the three‑chamber test. SB‑3CT and vehicle‑treated E4FAD mice were tested for A, B 
social interaction (one mouse vs empty cage) and C, D social memory (novel mouse vs familiar mouse) in the three‑chamber test. Time spent in A, 
C the whole chamber containing the mouse/empty cage and B, D the proximal zone surrounding the cages was measured (areas shown in green 
in each accompanying schematic). Animals were approximately 5 months of age and values represent mean ± SEM (N = 14, 5 males, 9 females 
for each group). No statistical significance was identified in any measures by ANOVA. E4FAD Apolipoprotein E4 x Familial Alzheimer’s disease, SEM 
Standard error of the mean, ANOVA Analysis of variance
(See figure on next page.)
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MMP9 inhibition can facilitate Aβ elimination across the 
BBB, the present studies evaluated the effect of MMP9 
inhibition in E4FAD mice. Moreover, to further validate 
the role of MMP9 in AD pathogenesis and neurobehavio-
ral dysfunction, we examined influence of MMP9 in AD 
by crossing 5xFAD mice with MMP9KO mice. Behavioral 
and psychological symptoms are common in AD and can 
significantly impact social interactions, leading to social 
withdrawal [60–64]. While mice are generally social 
animals [65], in the current studies the E4FAD mice did 
not display a preference for a mouse compared to the 
empty cage, indicative of reduced sociability, as meas-
ured using the three-chamber test. Similarly, though the 
5xFAD mice did spend significantly more time with the 
mouse than the empty cage, it did so to a lesser degree 
than the WT mice, consistent with previous studies dem-
onstrating reduced sociability in this mouse AD model, 
which progresses from 3 months of age onward [66]. The 
reduced social interaction by the 5xFAD mice was not 
apparent in the 5xFAD/MMP9KO mice, suggesting that 
removal of the MMP9 gene in this mouse AD model ben-
eficially impacted sociability. Furthermore, when a novel 
mouse was introduced, the WT, MMP9KO, and 5xFAD/
MMP9KO mice all spent significantly more time with 
the novel mouse versus the familiar mouse, however the 
5xFAD mice did not, indicating an impairment in social 
recognition memory, in line with previous reporting for 
this mouse AD model [67]. Notably, this impairment was 
Fig. 4 Spatial memory testing using the RAWM. SB‑3CT and vehicle‑treated E4FAD mice were tested for their ability to find the hidden platform 
in the RAWM. A A schematic of the maze layout is displayed. Mice were tested in nine trials per day for 5 days. B The number of incorrect entries 
made and C the time taken to find the maze were recorded and analyzed. D The total distance travelled per trial and E the average velocity while 
swimming was also evaluated. Animals were approximately 5 months of age and values represent mean ± SEM (N = 14, 5 males, 9 females for each 
group). No statistical significance was identified in any of the parameters by ANOVA. RAWM Radial arm water maze, E4FAD Apolipoprotein E4 x 
Familial Alzheimer’s disease, SEM Standard error of the mean, ANOVA Analysis of variance
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Fig. 5 Spatial memory testing of male mice using the RAWM. SB‑3CT and vehicle‑treated male E4FAD mice were tested for their ability to find the 
hidden platform in the RAWM. A A schematic of the maze layout is displayed. Mice were tested in nine trials per day for 5 days. B The number of 
incorrect entries made and C the time taken to find the maze were recorded and analyzed. D The total distance travelled per trial and E the average 
velocity while swimming was also evaluated. Values represent mean ± SEM (N = 5 males for each group). No statistical significance was identified in 
any of the parameters by ANOVA. RAWM Radial arm water maze, E4FAD Apolipoprotein E4 x Familial Alzheimer’s disease, SEM Standard error of the 
mean, ANOVA Analysis of variance
Fig. 6 Analysis of Aβ‑40 and Aβ‑42 levels in the whole parenchyma and cerebrovascular brain fractions. Aβ‑40 levels were examined in the A 
whole parenchyma, while Aβ‑42 levels were examined in the B whole parenchyma and C cerebrovasculature of E4FAD mice. Males and females 
were analyzed separately due to large differences in amyloid levels. Animals were approximately 5 months of age and values represent mean ± SEM 
(N = 14, 5 males, 9 females for each group). Statistical significance was determined by ANOVA followed by the BKY procedure. *p < 0.05, **p < 0.01 
***p < 0.001. Aβ Beta‑amyloid, E4FAD Apolipoprotein E4 x Familial Alzheimer’s disease, SEM Standard error of the mean, ANOVA Analysis of variance, 
BKY Benjamini, Krieger, and Yekutieli
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not observed when the MMP9 gene was absent. The CA2 
region of the hippocampus has been shown to be crucial 
for sociocognitive memory processing [68] and the hip-
pocampus shows a considerable elevation in Aβ levels in 
6 month-old 5xFAD mice [69].
As mentioned above, our previous research demon-
strated that inhibition of MMP9 mitigated Aβ-induced 
lipoprotein receptor shedding in the brains of apoE4 
mice in addition to increasing the transit of intracra-
nially injected Aβ from the brain to the periphery [17]. 
However, this does not appear to be the primary mecha-
nism driving the improved social memory in the 5xFAD/
MMP9KO mice since Aβ-40 and Aβ-42 levels in the 
parenchyma, cerebrovasculature, and Aβ-40 levels in the 
plasma remained constant across genotypes. Moreover, 
the levels of the lipoprotein receptors were unchanged 
between the different genotypes, suggesting there was 
no discernible impact on LRP1 and LDLR shedding 
when MMP9 was genetically absent. While removing the 
MMP9 gene in the 5xFAD mice did not result in obvi-
ous changes in Aβ disposition, it may have prevented the 
contribution of MMP9 to Aβ-induced cognitive deficits 
[10]. Mizoguchi et al. demonstrated that the injection of 
Aβ increases MMP9 expression and that this increase is 
associated with the development of cognitive impairment 
and neurotoxicity [10]. Recognition memory, as meas-
ured by the novel object recognition test, was impaired 
in Aβ-injected WT mice, but not MMP9KO mice or 
WT mice treated with an MMP inhibitor [10], coincid-
ing with the current studies using the three-chamber test. 
Like other mouse models of AD, 5xFAD mice display 
increased levels of MMP9 compared to WT mice [70, 
71], which could be contributing to the observed deficits 
in social recognition memory in these mice. Thus MMP9 
could be a target to improve social memory in AD or 
potentially other disease conditions.
While it was anticipated that MMP9 modulation would 
alter brain Aβ levels by facilitating lipoprotein receptor 
transit across the BBB, as demonstrated in our prior work 
[17], removing MMP9 may prevent other harmful actions 
of this enzyme and could explain the differences observed 
between the 5xFAD and the 5xFAD/MMP9KO mice. For 
instance, the degradation of matrix proteins in the vas-
cular basal lamina by MMP9, leading to BBB disruption, 
has been suggested to contribute to the brain damage 
that occurs following cerebral ischemia [72–74], effects 
that can be attenuated through MMP9 inhibition [25, 26]. 
Alternatively, the degradation of laminin or other matrix 
Fig. 7 Analysis of LDLR and LRP1 levels in the cerebrovasculature and the soluble brain fraction. Levels of the A, B LDLR receptor and C, D LRP1 
receptor were analyzed in the A, C soluble brain fraction and B, D the cerebrovasculature of SB‑3CT and vehicle‑treated E4FAD mice. Animals were 
approximately 5 months of age and values represent mean ± SEM (N = 14, 5 males, 9 females for each group). No statistically significant differences 
in LDLR or LRP1 levels were identified between vehicle or SB‑3CT‑treated mice in either brain fraction by ANOVA. LDLR Low‑density lipoprotein 
receptor, LRP1 Low density lipoprotein receptor‑related protein 1, E4FAD Apolipoprotein E4 x Familial Alzheimer’s disease, SEM Standard error of the 
mean, ANOVA Analysis of variance
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proteins by MMP9 throughout the brain may disrupt 
cell–matrix interactions and play a role in neuronal cell 
death [24], which could be attenuated through MMP9 
modulation. In fact, inhibition of MMP9 has been shown 
to reduce tissue damage, neutrophil infiltration, oxidative 
stress and degenerating neurons [7, 25, 26], all factors 
that could contribute to the impaired social memory in 
the 5xFAD mice [36, 75–79].
MMPs, in particular MMP9, have been suggested 
to have a generalized role in the maintenance of long-
term potentiation (LTP) and nonpathological synaptic 
plasticity in adult brains [80–83]. In previous studies, 
MMP9 inhibition led to the disruption of late-phase 
LTP [80–83], however, excessive MMP9 activity is del-
eterious to cells and MMP9 inhibition can enhance LTP 
when MMP9 activity is excessive and prolonged [84]. 
Under normal conditions, MMP9 activity is strictly regu-
lated and the transient proteolytic activity of the enzyme 
required for structural remodeling is focal and quickly 
terminated following its completion. Conversely, under 
pathological conditions, MMP9 activity is widespread 
and sustained, leading to abnormal synaptic plasticity 
and impairments in cognitive function [84, 85], which 
may describe the deficits in social recognition memory 
in the 5xFAD animals that were reversed in the 5xFAD/
MMP9KO mice.
In terms of sex, the effects of MMP9 modulation on 
social interaction and social memory in the 5xFAD 
group were largely driven by the male mice, which tend 
to show inherently less pathology compared to female 
mice in this AD model [36, 86]. This type of trend has 
been observed in clinical studies, where therapies appear 
to be more effective when administered early in the dis-
ease process and/or the pathology is less advanced [87, 
88]. Akin to our studies, prior in vivo work observed that 
male AD mice showed a markedly reduced social interac-
tion compared to female AD mice at 12  months of age, 
however these effects were reversed at 18 months of age 
as the female AD mice demonstrated less social interac-
tion than male AD mice [124]. In contrast to social rec-
ognition memory, spatial recognition memory was not 
impacted by MMP9 deletion or inhibition, however, 
male E4FAD mice treated with SB-3CT located the hid-
den platform slightly faster than the vehicle-treated mice 
over the course of the 5 days. This finding was not statis-
tically significant, possibly owing to the reduced number 
of mice in this subgroup analysis (N = 5) [89, 90]. Spatial 
disorientation is frequently observed in AD with patients 
Fig. 8 Analysis of MMP9 levels in SB‑3CT and vehicle‑treated E4FAD mice. A, B Levels of proMMP9 were examined in spleen samples from SB‑3CT 
and vehicle‑treated mice by zymography. A Zymography gel showing bands of proMMP9 in SB‑3CT‑treated and control animals. B Quantification 
of zymographic analysis. C, D Levels of total MMP9 as measured by ELISA analysis of the C cerebrovasculature and D the whole brain parenchyma 
of SB‑3CT and vehicle‑treated E4FAD mice. Animals were approximately 5 months of age and values represent mean ± SEM (N = 14, 5 males, 9 
females for each group). No statistical significance was identified in any fraction by ANOVA. MMP Matrix metallopeptidase, E4FAD Apolipoprotein E4 
x Familial Alzheimer’s disease, ELISA Enzyme linked immunosorbent assay, SEM Standard error of the mean, ANOVA Analysis of variance
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Fig. 9 Anxiety‑related behavior and locomotor activity in the OFT and the EPM. Wild type, 5xFAD, 5xFAD/MMP9KO and MMP9KO mice were 
tested using A, B, C the OFT and D, E, F, the EPM. A For the OFT, the duration spent in the outer, middle, and center areas of the circular arena 
was measured along with B the total distance travelled and C the average velocity. D For the EPM, the duration spent in the closed and open 
arms was measured together with E the total distance travelled and F the average velocity. Animals were approximately 6 months of age and 
values represent mean ± SEM (N = 12, 6 males, 6 females for each group). Statistical significance was determined by (A, D) ANOVA and (B, C, E, 
F) one‑way ANOVA followed by the BKY procedure. *p < 0.05, **p < 0.01. OFT Open field test, EPM Elevated plus maze, WT Wild‑type, MMP Matrix 
metallopeptidase, FAD Familial Alzheimer’s disease, MMP9KO MMP9 knockout, SEM Standard error of the mean, ANOVA Analysis of variance, BKY 
Benjamini, Krieger, and Yekutieli
(See figure on next page.)
Fig. 10 Testing social interaction and social memory using the three‑chamber test. Wild type, 5xFAD, 5xFAD/MMP9KO and MMP9KO mice were 
tested for A, B social interaction (one mouse vs empty cage) and C, D social memory (novel mouse vs familiar mouse) in the three‑chamber test. 
Time spent in A, C the whole chamber containing the mouse/empty cage and B, D the proximal zone surrounding the cages was measured 
(areas shown in green in each accompanying schematic). Animals were approximately 6 months of age and values represent mean ± SEM 
(N = 12, 6 males, 6 females for each group). Statistical significance was determined by ANOVA followed by the BKY procedure. *p < 0.05, **p < 0.01, 
***p < 0.001, ****p < 0.0001. WT Wild‑type, MMP Matrix metallopeptidase, FAD Familial Alzheimer’s disease, MMP9KO MMP9 knockout, SEM Standard 
error of the mean, ANOVA Analysis of variance, BKY Benjamini, Krieger, and Yekutieli
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displaying impaired visuospatial memory [91–93]. Spa-
tial recognition memory has been previously shown to be 
impaired in 4-month-old E4FAD mice using the two-trial 
Y-maze and the Morris Water Maze [94], however, in 
the RAWM used in our studies, the control E4FAD mice 
continued to learn each day, making few mistakes by day 
5 and quickly finding the platform. Likewise, the perfor-
mance of the 5xFAD mice at 6 months of age was similar 
to the WT mice as they did not exhibit deficits in spa-
tial memory. Deficits in spatial memory and recognition 
memory are both initial symptoms of AD [95], though 
spatial memory typically presents earlier in the spec-
trum of cognitive impairment than recognition memory 
[67, 96–99]. In contrast, the 6-month-old 5xFAD mice in 
the current studies displayed impairment of social rec-
ognition memory but not spatial memory. While mem-
ory impairment in this 5xFAD mouse strain has been 
detected as young as 1  month of age through the Mor-
ris water maze [100, 101], others have found that 5xFAD 
mice display normal spatial memory function in this test 
until 7 months of age [102] or even up to 12 months of 
age [103]. Likewise, recognition memory has been shown 
to emerge at 4 months of age [103] in one study and at 
9 months of age in another [67]. These findings indicate 
behavioral observations can vary considerably from one 
experiment to another and memory impairment can be 
specific to context, modality, and/or environment [66]. 
Because the E4FAD and the 5xFAD made few errors 
by day 5, it is difficult to discern whether the SB-3CT 
treatment or the MMP9 gene knockout had any impact 
on spatial memory in these studies. Future studies may 
need to assess the effect of both approaches in older mice 
where the deficits in spatial memory are more apparent, 
while accounting for potential differences in gender.
It has been demonstrated that 5xFAD mice display 
reduced anxiety in the EPM compared to WT mice, 
as measured by increased time spent in the open arms 
compared to the closed arms [75, 104, 105]. In our 
studies, pharmacological and genetic modulation of 
MMP9 in the AD models increased the time spent in 
the closed arms of the EPM, though only the pharma-
cological studies reached statistical significance. In the 
OFT, the reduced time spent in the outer areas of the 
arena and increased time in the middle of the arena 
by the 5xFAD mice compared to all other genotypes 
indicates reduced anxiety or tendency toward disin-
hibition. Disinhibition is one of the neuropsychiatric 
symptoms seen in AD patients, manifesting as impul-
sive behavior and the disregard for danger [106–108]. 
The removal of MMP9 appeared to mitigate the anxi-
olytic behavior in the 5xFAD mice as the behavioral 
pattern of the 5xFAD/MMP9KO mice in the OFT was 
similar to the WT mice. It is also necessary to analyze 
locomotor behavior in these tests since anxiety meas-
ures can be confounded by levels of activity [109]. The 
increased locomotor activity in the 5xFAD mice has 
been previously documented and attributed to altera-
tions in neurotransmitter levels [67, 110] in addition to 
decreased anxiety [111]. In the present studies, 5xFAD/
MMP9KO mice had significantly lower locomotor 
activity compared to the 5xFAD mice as measured by 
distance travelled and average velocity, again suggesting 
MMP9 may be influencing anxiety-related behavior. In 
fact, MMP9 has been associated with an increased sus-
ceptibility to anxiety disorders [112] as well as showing 
elevated levels in other psychiatric illnesses [113–115]. 
Human genomic and proteomic studies have revealed 
that aberrant inflammatory responses, gene regula-
tion, and synaptic plasticity are major players under-
lying neuropsychiatric disorders. As MMP9 has been 
implicated in both the inflammatory response and syn-
aptic plasticity, its contribution to the development of 
psychiatric symptoms may be mediated through these 
processes [115]. However, further research needs to be 
conducted to understand the precise mechanisms that 
are involved.
Limitations
Overall, while we did observe significant differences in 
social memory between the WT, 5XFAD, and 5XFAD/
MMP9KO mice, namely the 5xFAD mice exhibited 
social memory deficits compared to both the WT and 
the 5XFAD/MMP9KO mice, these effects were relatively 
modest. It is anticipated, these differences would be more 
apparent with increased age and/or altered brain pathol-
ogy in the 5xFAD mice. The studies conducted by Mizo-
guchi et al., point to the direct involvement of MMP9 in 
Aβ-induced cognitive deficits as MMP9 inhibition and 
knockout prevented the impairment of social recogni-
tion memory [116]. Therefore, a more detailed analysis of 
Fig. 11 Testing social interaction and social memory of male mice using the three‑chamber test. Male wild type, 5xFAD, 5xFAD/MMP9KO and 
MMP9KO mice were tested for A, B social interaction (one mouse vs empty cage) and C, D social memory (novel mouse vs familiar mouse) in 
the three‑chamber test. Time spent in A, C the whole chamber containing the mouse/empty cage and B, D the proximal zone surrounding the 
cages was measured (areas shown in green in each accompanying schematic). Animals were approximately 6 months of age and values represent 
mean ± SEM (N = 6 males for each group). Statistical significance was determined by ANOVA followed by the BKY procedure. *p < 0.05, **p < 0.01, 
***p < 0.001. WT Wild‑type, MMP Matrix metallopeptidase, FAD Familial Alzheimer’s disease, MMP9KO MMP9 knockout, SEM Standard error of the 
mean, ANOVA Analysis of variance, BKY Benjamini, Krieger, and Yekutieli
(See figure on next page.)
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Fig. 12 Testing spatial memory using the RAWM. Wild type, 5xFAD, 5xFAD/MMP9KO and MMP9KO mice were tested for their ability to find the 
hidden platform in the RAWM. A A schematic of the maze layout is displayed. Mice were tested in nine trials per day for 5 days. B The number of 
incorrect entries made and C the time taken to find the maze were recorded and analyzed. D The total distance travelled per trial and E the average 
velocity while swimming were also evaluated. Animals were approximately 6 months of age and values represent mean ± SEM (N = 12, 6 males, 6 
females for each group). No statistical significance was identified in any of the parameters by ANOVA. RAWM Radial arm water maze, WT Wild‑type, 
MMP Matrix metallopeptidase, FAD Familial Alzheimer’s disease, MMP9KO MMP9 knockout, SEM Standard error of the mean, ANOVA Analysis of 
variance
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specific changes in the Aβ population following MMP9 
removal in our studies, for instance shifts in the brain 
location, forms, or toxic species of Aβ, may be neces-
sary to understand the influence of MMP9 on behavio-
ral performance. Lastly, in the current studies all animals 
underwent the same series of behavioral tests, and thus 
can be reasonably compared across groups. However, it is 
worth noting that animals exposed to multiple behavioral 
paradigms in a relatively short period of time can develop 
a training effect, in which participation in one task could 
influence the response in a subsequent task.
Removing the MMP9 gene in the 5xFAD mice did 
result in more pronounced differences in neurobehav-
ior compared to pharmacological inhibition of MMP9 
in the E4FAD animals, which may be due to several fac-
tors. Most notable, in the 5XFAD/MMP9KO animals, 
MMP9 is mitigated earlier (from birth), more extensively 
(complete removal), and for a longer period of time (lifes-
pan) than the pharmacological studies. That having been 
said, the MMP9KO studies occurred in the presence of 
murine apoE, as opposed to the human apoE isoforms. 
ApoE-driven AD pathologies differ from pure amyloid 
pathologies [117, 118] and our prior work indicates apoE 
can regulate MMP9 disposition in the brain, and the 
apoE4 isoform in particular is associated with elevated 
MMP9 levels and activity [18]. Therefore, a limitation of 
the genetic knockout studies may be the absence of the 
apoE4 isoform which, as mentioned, exacerbates MMP9 
activity and is closely associated with AD pathogenesis. 
It is also worth noting that the removal of a gene at birth 
may not entirely reflect its role in a disease process, par-
ticularly for age-related disorders, as adaptation or com-
pensation by other genes may occur prior to disease 
onset. As such, the use of a conditional knockout model 
or adeno-associated viruses (AAV) may provide a more 
accurate representation of the impact of MMP9 in AD 
and the potential for therapeutic intervention.
Fig. 13 Analysis of Aβ‑40 levels in the cerebrovasculature, plasma, and whole parenchyma brain fractions. Aβ‑40 levels were examined in the 
A cerebrovasculature, B whole parenchyma, and C plasma of 5xFAD, 5xFAD/MMP9KO and 5xFAD/MMP9KO‑het mice. Males and females were 
analyzed separately due to large differences in amyloid levels. Animals were approximately 6 months of age and values represent mean ± SEM 
(N = 12, 6 males, 6 females for each group). Statistical significance was determined by ANOVA followed by the BKY procedure. *p < 0.05, **p < 0.01, 
***p < 0.001. Aβ Beta‑amyloid, FAD Familial Alzheimer’s disease, MMP Matrix metallopeptidase, MMP9KO MMP9 knockout, MMP9KO-het MMP9KO 
heterozygous, SEM Standard error of the mean, ANOVA Analysis of variance, BKY Benjamini, Krieger, and Yekutieli
Fig. 14 Analysis of Aβ‑42 levels in the cerebrovasculature and whole parenchyma brain fractions. Aβ‑42 levels were examined in the A 
cerebrovasculature, and B whole parenchyma of 5xFAD, 5xFAD/MMP9KO and 5xFAD/MMP9KO‑het mice. Males and females were analyzed 
separately due to large differences in amyloid levels. Animals were approximately 6 months of age and values represent mean ± SEM (N = 12, 6 
males, 6 females for each group). Statistical significance was determined by ANOVA followed by the BKY procedure. **p < 0.01, ****p < 0.0001. Aβ 
Beta‑amyloid, FAD Familial Alzheimer’s disease, MMP Matrix metallopeptidase, MMP9KO MMP9 knockout, MMP9KO-het MMP9KO heterozygous, SEM 
Standard error of the mean, ANOVA Analysis of variance, BKY Benjamini, Krieger, and Yekutieli
Page 20 of 25Ringland et al. BMC Neurosci           (2021) 22:39 
The altered anxiety in the E4FAD mice indicates that 
treatment with SB-3CT may be efficacious, however, 
due to limitations in detection, the proteolytic activity 
of MMP9 in the brain could not be measured and we 
could not confirm target engagement. This finding is 
consistent with other reports owing to the rapid degra-
dation of the activated MMP9 enzyme in vivo [24]. The 
mechanism of action of SB-3CT is to modulate MMP9 
activity, not MMP9 expression (119). As expected, total 
MMP9 levels in the E4FAD brains remained unaltered, 
emphasizing that MMP9 expression is not a good indi-
cator of target engagement when assessing SB-3CT. 
Owing to this limitation, it is not certain whether the 
observed effect on anxiety in the current studies was 
caused by the inhibition of MMP9 activity or another 
effect of the drug. In prior reporting, the same dose of 
SB-3CT used in our studies showed significant reduc-
tions in MMP9 activity in the brain using a treatment 
paradigm more acute than that used in the present 
studies [6, 31]. Thus, it seems likely MMP9 activity was 
inhibited in the current studies, but a more chronic 
treatment paradigm may be necessary to overcome 
the AD phenotype. Moreover, intervention at an ear-
lier stage may be required since the SB-3CT treat-
ment in the current studies began at 4-months of age 
in the E4FAD mice, a time at which brain pathology is 
already apparent [102, 120]. Additionally, both MMP9 
and apoE4 have been implicated in early AD pathology 
before the onset of cognitive impairment [55–59], so 
therapeutic approaches targeting MMP9 may require 
early administration to see the greatest benefits.
The inherent limitations of transgenic AD mouse 
models when investigating the underlying mecha-
nisms and potential treatments for sporadic AD must 
also be noted. 5xFAD mice are based on early-onset 
AD and co-express five FAD mutations, resulting in 
excessively high levels of Aβ-42 at a relatively early 
age, and therefore do not convincingly represent the 
chronic age-related progression of sporadic AD pathol-
ogy, which represents > 97% of the AD population [121, 
122]. That said, while AD pathology is well established 
at 6 months of age in the AD models used in the cur-
rent studies, and age is a prominent factor in AD patho-
genesis, the pathological or behavioral deficits may 
have been more apparent (and perhaps the impact of 
MMP9 modulation) if these animals were interrogated 
at a more advanced age (> 12  months). The inability 
to recapitulate sporadic AD in animal models due to 
the complex and heterogenous nature of the disease 
has hindered the development of effective treatments 
(Additional file  1: Figure S1). The use of more accu-
rate animal models of late-onset AD would facilitate 
the drug development process in AD and identify more 
appropriate drug candidates for clinical testing. With 
Fig. 15 Analysis of LDLR and LRP1 levels in the cerebrovasculature and the soluble brain fraction. Levels of the A, B LDLR receptor and C, D LRP1 
receptor were analyzed in the A, C soluble brain fraction and B, D the cerebrovasculature of wild type, 5xFAD, 5xFAD/MMP9KO, 5xFAD/MMP9KO‑het 
and MMP9KO mice. Animals were approximately 6 months of age and values represent mean ± SEM (N = 12, 6 males, 6 females for each group). No 
statistically significant differences in LDLR or LRP1 levels were identified between any genotype in either brain fraction by ANOVA. LDLR Low‑density 
lipoprotein receptor, LRP1 Low density lipoprotein receptor‑related protein 1, FAD Familial Alzheimer’s disease, MMP Matrix metallopeptidase, 
MMP9KO MMP9 knockout, MMP9KO-het MMP9KO heterozygous, SEM Standard error of the mean, ANOVA Analysis of variance
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respect to the current studies, using more representa-
tive models of sporadic AD would likely improve inves-
tigation into the role of MMP9 in AD pathogenesis and 
cognitive dysfunction, and its potential as a therapeutic 
target for this disorder.
Conclusions
MMP9 levels in the brain are elevated in a variety of neu-
rological disorders, including AD, and contribute to dis-
ease formation and progression. In the current studies, 
MMP9 modulation in AD animals improved sociability 
and social recognition memory, particularly in male mice, 
in addition to reducing anxiety, while spatial learning and 
memory was unaffected. In our prior work MMP9 inhibi-
tion increased Aβ elimination across the BBB, however, 
modulating MMP9 in the present studies did not alter Aβ 
tissue levels in AD animals. As such, MMP9 appears to 
mediate certain neurobehavioral deficits in AD, such as 
anxiety and social recognition memory, but these effects 
are independent of Aβ levels in the brain. While thera-
peutic strategies targeting MMP9 could improve some 
aspects of neurobehavioral dysfunction in AD, addi-
tional studies are needed to better understand the role of 
MMP9 in neurological disease.
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